Snapshot from Sep 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Business corporate action

XORTX terminates IR agreement, delists TSXV

Analysis based on 7 articles · First reported Aug 28, 2026 · Last updated Aug 28, 2026

Sentiment
-10
Attention
1
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The termination of the IR agreement and return of funds may reduce near-term marketing expenses but also signals reduced investor outreach, potentially dampening investor sentiment. The voluntary delisting from the TSX Venture Exchange could reduce liquidity and visibility for Canadian investors, while the company remains listed on Nasdaq.

Pharmaceuticals Biotechnology

XORTX Therapeutics Inc. announced on August 28, 2026 that it terminated its investor relations and marketing agreement with IR Agency LLC, effective August 7, 2026. The agreement, dated May 13, 2026, had a 90-day term and a fee of US$2.5 million, which was fully paid in advance. Under mutual agreement, the arrangement was rescinded, services discontinued, and the funds returned to XORTX on August 14, 2026. The company postponed its investor relations program while it completes its voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. XORTX also announced that Computershare will become its transfer agent and registrar, replacing TSX Trust Company, effective September 1, 2026. Additionally, the company disclosed that US$240,000 in finder's fees were paid in connection with its acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program, which closed on April 13, 2026.

80 XORTX Therapeutics terminated agreement IR Agency LLC
80 IR Agency LLC returned funds XORTX Therapeutics
60 XORTX Therapeutics postponed program
30 XORTX Therapeutics changed transfer agent Computershare
20 XORTX Therapeutics disclosed finder's fees Vectus Biosystems
stock
XORTX terminated its IR agreement, postponed its investor relations program, and is proceeding with voluntary delisting from the TSXV. These actions aim to reduce costs and regulatory complexity but may reduce investor visibility.
Importance 100.0 Sentiment -10.0
priv
IR Agency LLC had its agreement terminated and returned US$2.5 million in fees to XORTX, losing expected revenue from the marketing program.
Importance 70.0 Sentiment -20.0
exch
XORTX is voluntarily delisting from the TSXV, reducing the exchange's listed companies and potentially its trading volume.
Importance 60.0 Sentiment -10.0
exch
XORTX remains listed on Nasdaq, which continues to be its primary exchange after the TSXV delisting.
Importance 50.0 Sentiment 10.0
stock
XORTX disclosed finder's fees related to its acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program, clarifying the transaction's costs.
Importance 40.0 Sentiment 0.0
curr
The US dollar is the currency in which the IR agreement fee and finder's fees were denominated, reflecting the company's US-based financial transactions.
Importance 30.0 Sentiment 0.0
stock
Computershare will become XORTX's transfer agent and registrar, gaining a new client.
Importance 30.0 Sentiment 10.0
priv
TSX Trust Company will be replaced as XORTX's transfer agent, losing that business.
Importance 20.0 Sentiment -10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.